002437 誉衡药业
交易中 06-04 10:09:57
资讯
新帖
简况
誉衡药业：公司自有产品西格列汀二甲双胍缓释片为治疗2型糖尿病的药品
证券之星 · 58分钟前
誉衡药业：公司自有产品西格列汀二甲双胍缓释片为治疗2型糖尿病的药品
誉衡药业：截止到2026年5月20日，公司股东人数为9.44万户
证券之星 · 58分钟前
誉衡药业：截止到2026年5月20日，公司股东人数为9.44万户
誉衡药业(002437)5月20日股东户数9.44万户，较上期增加1.29%
证券之星 · 06-01 17:43
誉衡药业(002437)5月20日股东户数9.44万户，较上期增加1.29%
誉衡药业：截止到2026年5月20日，公司股东人数为9.44万户
证券之星 · 05-21
誉衡药业：截止到2026年5月20日，公司股东人数为9.44万户
誉衡药业：公司将持续通过夯实主营业务、加强精细化管理等方式努力做好业绩
证券之星 · 05-19
誉衡药业：公司将持续通过夯实主营业务、加强精细化管理等方式努力做好业绩
誉衡药业：公司已完成内部组织架构的调整及精简
证券之星 · 05-19
誉衡药业：公司已完成内部组织架构的调整及精简
誉衡药业：公司与第一三共终止产品推广合作
证券之星 · 05-19
誉衡药业：公司与第一三共终止产品推广合作
誉衡药业（002437）披露关于使用公积金弥补亏损通知债权人的公告，5月18日股价上涨0.32%
证券之星 · 05-18
誉衡药业（002437）披露关于使用公积金弥补亏损通知债权人的公告，5月18日股价上涨0.32%
誉衡药业：截止到2026年5月10日，公司股东人数为9.32万户
证券之星 · 05-12
誉衡药业：截止到2026年5月10日，公司股东人数为9.32万户
每周股票复盘：誉衡药业（002437）Q1净利增57.55%
证券之星 · 05-03
每周股票复盘：誉衡药业（002437）Q1净利增57.55%
誉衡药业(002437)4月20日股东户数10.06万户，较上期增加4.47%
证券之星 · 04-28
誉衡药业(002437)4月20日股东户数10.06万户，较上期增加4.47%
图解誉衡药业年报：第四季度单季净利润同比增长170.21%
证券之星 · 04-28
图解誉衡药业年报：第四季度单季净利润同比增长170.21%
誉衡药业：截止到2026年4月20日，公司股东人数为10.06万户
证券之星 · 04-21
誉衡药业：截止到2026年4月20日，公司股东人数为10.06万户
誉衡药业最新公告：全资子公司甲氨蝶呤注射液获准上市
证券之星 · 04-17
誉衡药业最新公告：全资子公司甲氨蝶呤注射液获准上市
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
21世纪经济报道 · 04-15
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
誉衡药业最新公告：2025年净利润同比增长61.93%
证券之星 · 04-14
誉衡药业最新公告：2025年净利润同比增长61.93%
誉衡药业：截至2026年4月10日，公司股东人数为9.63万户
证券之星 · 04-14
誉衡药业：截至2026年4月10日，公司股东人数为9.63万户
誉衡药业：公司骨科产品主要为鹿瓜多肽注射液
证券之星 · 04-01
誉衡药业：公司骨科产品主要为鹿瓜多肽注射液
股市必读：誉衡药业(002437)股东户数9.74万户，较上期减少1.12%
证券之星 · 03-25
股市必读：誉衡药业(002437)股东户数9.74万户，较上期减少1.12%
股市必读：誉衡药业（002437）3月23日收盘跌7.19%，主力净流出1307.12万元
证券之星 · 03-24
股市必读：誉衡药业（002437）3月23日收盘跌7.19%，主力净流出1307.12万元
暂无数据
公司概况
公司名称：
哈尔滨誉衡药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-06-23
主营业务：
哈尔滨誉衡药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是维生素类药物、心脑血管药物、骨科药物、电解质类药物、抗肿瘤药物、抗感染药物、其他用药领域、糖尿病类药物、镇痛类药物。
发行价格：
50.00
{"stockData":{"symbol":"002437","market":"SZ","secType":"STK","nameCN":"誉衡药业","latestPrice":2.86,"timestamp":1780538997000,"preClose":2.91,"halted":0,"volume":12756545,"delay":0,"changeRate":-0.0172,"floatShares":2100000000,"shares":2230000000,"eps":0.1846,"marketStatus":"交易中","change":-0.05,"latestTime":"06-04 10:09:57","open":2.9,"high":2.9,"low":2.85,"amount":36662200,"amplitude":0.0172,"askPrice":2.87,"askSize":4842,"bidPrice":2.86,"bidSize":6221,"shortable":0,"etf":0,"ttmEps":0.1846,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1780543800000},"marketStatusCode":2,"adr":0,"adjPreClose":2.91,"symbolType":"stock","openAndCloseTimeList":[[1780536600000,1780543800000],[1780549200000,1780556400000]],"highLimit":3.2,"lowLimit":2.62,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2229868126,"isCdr":false,"pbRate":2.72,"roa":"--","peRate":15.492958,"roe":"4.05%","epsLYR":0.1719,"committee":0.140324,"marketValue":6377000000,"turnoverRate":0.0061,"status":1,"floatMarketCap":6006000000},"requestUrl":"/m/hq/s/002437/tweets","defaultTab":"tweets","newsList":[{"id":"2640339441","title":"誉衡药业：公司自有产品西格列汀二甲双胍缓释片为治疗2型糖尿病的药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2640339441","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640339441?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:12","pubTimestamp":1780535530,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：本月是糖尿病学界的“黄金月”，全球最高规格的ADA年会与国内中青年医师论坛密集召开。公司有治疗糖尿病方面的药品吗？誉衡药业回复：您好，公司自有产品西格列汀二甲双胍缓释片为治疗2型糖尿病的药品，感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0028","BK0239","002437","BK0060","BK0095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640133943","title":"誉衡药业：截止到2026年5月20日，公司股东人数为9.44万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2640133943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640133943?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:12","pubTimestamp":1780535528,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司截至2026年5月20日股东数是多少？谢谢。誉衡药业回复：您好，截止到2026年5月20日，公司股东人数为9.44万户，感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002437","BK0095","BK0060","BK0239","BK0028","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640293018","title":"誉衡药业(002437)5月20日股东户数9.44万户，较上期增加1.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640293018","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640293018?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:43","pubTimestamp":1780306987,"startTime":"0","endTime":"0","summary":"证券之星消息，近日誉衡药业披露，截至2026年5月20日公司股东户数为9.44万户，较5月10日增加1200.0户，增幅为1.29%。在化学制药行业个股中，誉衡药业股东户数高于行业平均水平，截至5月20日，化学制药行业平均股东户数为3.56万户。从股价来看，2026年5月10日至2026年5月20日，誉衡药业区间跌幅为5.42%，在此期间股东户数增加1200.0户，增幅为1.29%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100027053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002437","BK0077","BK0188","BK0028","BK0095","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637880525","title":"誉衡药业：截止到2026年5月20日，公司股东人数为9.44万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2637880525","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637880525?lang=zh_cn&edition=full","pubTime":"2026-05-21 11:34","pubTimestamp":1779334482,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)05月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到5月19日，贵司股东有多少名？誉衡药业回复：您好，截止到2026年5月20日，公司股东人数为9.44万户，感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100018830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0095","002437","BK0077","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636883324","title":"誉衡药业：公司将持续通过夯实主营业务、加强精细化管理等方式努力做好业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2636883324","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636883324?lang=zh_cn&edition=full","pubTime":"2026-05-19 09:12","pubTimestamp":1779153129,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：公司2025年年报致股东信中提到“公司加权平均净资产收益率提升至18%，盈利质量持续显著提升”。请问公司如何看待ROE指标，对2026年以及将来有什么展望？誉衡药业回复：您好，近三年来，公司在资产质量、盈利能力、运营效率等方面取得了有效的改善和提升，后续，公司将持续通过夯实主营业务、加强精细化管理等方式努力做好业绩。谢谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900010213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0077","002437","BK0095","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636838268","title":"誉衡药业：公司已完成内部组织架构的调整及精简","url":"https://stock-news.laohu8.com/highlight/detail?id=2636838268","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636838268?lang=zh_cn&edition=full","pubTime":"2026-05-19 09:12","pubTimestamp":1779153129,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请介绍一下公司2026年的营销改革，目前在终端覆盖与渗透率方面有何进展？谢谢誉衡药业回复：您好，公司积极推进营销改革工作，截至目前，公司已完成内部组织架构的调整及精简，并加大精细化管理力度。公司主要产品的市场覆盖情况请您参考公司2025年年度报告“第三节 管理层讨论与分析”中“公司及主要产品的行业地位”，谢谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900010212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0095","002437","BK0077","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636838208","title":"誉衡药业：公司与第一三共终止产品推广合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2636838208","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636838208?lang=zh_cn&edition=full","pubTime":"2026-05-19 09:12","pubTimestamp":1779153126,"startTime":"0","endTime":"0","summary":"谢谢誉衡药业回复：您好。2、剔除与第一三共终止合作这个因素，公司2026年一季度整体收入有7%以上的增长，具体详见4月28日披露的《誉衡药业：002437誉衡药业投资者关系管理信息20260428》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900010210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0077","002437","BK0239","BK0028","BK0188","BK0095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636074451","title":"誉衡药业（002437）披露关于使用公积金弥补亏损通知债权人的公告，5月18日股价上涨0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636074451","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636074451?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:38","pubTimestamp":1779115096,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，誉衡药业报收于3.16元，较前一交易日上涨0.32%，最新总市值为70.46亿元。近日，哈尔滨誉衡药业股份有限公司披露《关于使用公积金弥补亏损通知债权人的公告》。根据相关规定，公司需通知债权人，债权人自接到通知之日起30日内或未接到通知的自公告披露之日起45日内，可要求公司清偿债务或提供担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800037817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002437","BK0095","BK0188","BK0239","BK0077","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634298377","title":"誉衡药业：截止到2026年5月10日，公司股东人数为9.32万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2634298377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634298377?lang=zh_cn&edition=full","pubTime":"2026-05-12 15:07","pubTimestamp":1778569634,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)05月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2026年5月10日公司的股东总数是多少？谢谢誉衡药业回复：您好，截止到2026年5月10日，公司股东人数为9.32万户，感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200019850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0095","BK0188","BK0077","002437","BK0239","BK0060","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632746646","title":"每周股票复盘：誉衡药业（002437）Q1净利增57.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632746646","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632746646?lang=zh_cn&edition=full","pubTime":"2026-05-03 02:54","pubTimestamp":1777748049,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，誉衡药业报收于3.52元，较上周的3.7元下跌4.86%。本周，誉衡药业4月27日盘中最高价报3.79元。户均持股数量由2.32万股降至2.22万股，户均持股市值为8.53万元。业绩披露要点财务报告2026年一季报显示，公司主营收入5.39亿元，同比下降2.2%；归母净利润9492.61万元，同比上升57.55%；扣非净利润6294.22万元，同比上升26.56%；负债率23.43%，投资收益43.6万元，财务费用77.35万元，毛利率45.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","BK0077","BK0095","002437","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630837230","title":"誉衡药业(002437)4月20日股东户数10.06万户，较上期增加4.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630837230","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630837230?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:51","pubTimestamp":1777369917,"startTime":"0","endTime":"0","summary":"证券之星消息，近日誉衡药业披露，截至2026年4月20日公司股东户数为10.06万户，较4月10日增加4300.0户，增幅为4.47%。在化学制药行业个股中，誉衡药业股东户数高于行业平均水平，截至4月20日，化学制药行业平均股东户数为3.57万户。从股价来看，2026年4月10日至2026年4月20日，誉衡药业区间涨幅为5.77%，在此期间股东户数增加4300.0户，增幅为4.47%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800052778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0077","002437","BK0095","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630231927","title":"图解誉衡药业年报：第四季度单季净利润同比增长170.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630231927","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630231927?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:43","pubTimestamp":1777311786,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业2025年年报显示，当年度公司主营收入21.35亿元，同比下降12.51%；归母净利润3.77亿元，同比上升61.93%；扣非净利润1.99亿元，同比上升8.64%；其中2025年第四季度，公司单季度主营收入4.7亿元，同比下降19.34%；单季度归母净利润1.33亿元，同比上升170.21%；单季度扣非净利润2098.3万元，同比下降48.09%；负债率26.32%，投资收益1.37亿元，财务费用-34.05万元，毛利率45.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800004732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002437"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629508613","title":"誉衡药业：截止到2026年4月20日，公司股东人数为10.06万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2629508613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629508613?lang=zh_cn&edition=full","pubTime":"2026-04-21 16:09","pubTimestamp":1776758949,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)04月21日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！敬请发布截至今天4月中旬末公司股东户数信息。谢谢！致礼！誉衡药业回复：您好，截止到2026年4月20日，公司股东人数为10.06万户，感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100036129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0095","002437","BK0077","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628320189","title":"誉衡药业最新公告：全资子公司甲氨蝶呤注射液获准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2628320189","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628320189?lang=zh_cn&edition=full","pubTime":"2026-04-17 21:00","pubTimestamp":1776430810,"startTime":"0","endTime":"0","summary":"誉衡药业(002437.SZ)公告称，公司全资子公司哈尔滨誉衡制药有限公司申报的多规格(预灌封注射器)甲氨蝶呤注射液收到国家药品监督管理局核准签发的《药品注册证书》。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700043475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0095","BK0188","BK0028","BK0239","BK0060","002437"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045478","title":"诺和诺德与OpenAI达成战略合作；再生元牵手Telix","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045478","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627045478?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:01","pubTimestamp":1776211308,"startTime":"0","endTime":"0","summary":"政策动向国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作国家医疗保障局近日在全国范围内组织开展2026年定点医药机构违法违规使用医保基金自查自纠工作。自查自纠聚焦重点领域“逐渐细化、持续深化”。在既往心血管内科、骨科、血液净化、康复、医学影像、临床检验、肿瘤、麻醉、重症医学等9个重点领域的基础上，本年度进一步将口腔、内分泌、精神医学3个领域纳入自查自纠范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705224747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705224747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0154236417.USD","BK4585","BK4532","IE00BZ1G4Q59.USD","BK4599","LU1093756325.SGD","002437","LU1093756168.USD","NVO","NVOH","300558","600196","NVOX","IE00BKVL7J92.USD","301087","BK4588","REGN","688177","600513","603087","BK4007","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627417967","title":"誉衡药业最新公告：2025年净利润同比增长61.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627417967","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627417967?lang=zh_cn&edition=full","pubTime":"2026-04-14 18:29","pubTimestamp":1776162576,"startTime":"0","endTime":"0","summary":"誉衡药业(002437.SZ)公告称，公司发布2025年度业绩快报，实现营业收入21.35亿元，同比下降12.51%；归属于上市公司股东的净利润为3.77亿元，同比增长61.93%。业绩变动主要系核心产品销量增长、降本增效成果显著，以及收到出售子公司股权尾款及利息计入投资收益所致。注：Q4净利润1.33亿，Q3净利润1.09亿，据此计算，Q4净利润环比增长21%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400031017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002437"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627415172","title":"誉衡药业：截至2026年4月10日，公司股东人数为9.63万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2627415172","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627415172?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:57","pubTimestamp":1776153427,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)04月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截止4月10日的股东人数是多少？谢谢。誉衡药业回复：您好，截至2026年4月10日，公司股东人数为9.63万户，感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400023806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0095","BK0028","BK0060","BK0239","002437","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624560545","title":"誉衡药业：公司骨科产品主要为鹿瓜多肽注射液","url":"https://stock-news.laohu8.com/highlight/detail?id=2624560545","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624560545?lang=zh_cn&edition=full","pubTime":"2026-04-01 15:06","pubTimestamp":1775027185,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)03月31日在投资者关系平台上答复投资者关心的问题。投资者提问：2025年中报显示公司骨科药物占比高达78%，毛利率那么高，该药品是否为公司独家销售？未来有扩产计划吗？誉衡药业回复：您好，公司骨科产品主要为鹿瓜多肽注射液，该产品是公司自主生产和销售的产品。该产品市场占有率处于同类产品第一位，市场份额超过50%。目前，公司现有产能可以满足市场需求。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100022017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0095","BK0188","BK0028","BK0239","BK0060","002437"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622090151","title":"股市必读：誉衡药业(002437)股东户数9.74万户，较上期减少1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622090151","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622090151?lang=zh_cn&edition=full","pubTime":"2026-03-25 03:07","pubTimestamp":1774379233,"startTime":"0","endTime":"0","summary":"截至2026年3月24日收盘，誉衡药业报收于3.11元，上涨4.71%，换手率2.78%，成交量58.09万手，成交额1.78亿元。交易信息汇总资金流向3月24日主力资金净流入93.05万元；游资资金净流出983.43万元；散户资金净流入890.38万元。股本股东变化股东户数变动近日誉衡药业披露，截至2026年3月20日公司股东户数为9.74万户，较3月10日减少1100.0户，减幅为1.12%。户均持股数量由上期的2.27万股增加至2.29万股，户均持股市值为7.33万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500004155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002437","BK0188","BK0077","BK0060","BK0028","BK0095","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621854590","title":"股市必读：誉衡药业（002437）3月23日收盘跌7.19%，主力净流出1307.12万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621854590","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621854590?lang=zh_cn&edition=full","pubTime":"2026-03-24 02:11","pubTimestamp":1774289472,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，誉衡药业报收于2.97元，下跌7.19%，换手率3.54%，成交量73.93万手，成交额2.25亿元。来自交易信息汇总：当日主力资金净流出1307.12万元，游资与散户资金呈净流入态势。交易信息汇总股价提醒3月23日誉衡药业收盘报2.97元，跌7.19%，当日成交7393.42万元。根据收盘数据统计，该股已连续3日下跌。前10个交易日资金流向情况：主力资金累计净流出2673.85万元，股价累计下跌10.5%；融资余额累计增加9.27万元，融券余量累计增加0股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400001994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0028","BK0095","BK0188","BK0077","002437"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780539000806,"stockEarnings":[{"period":"1week","weight":-0.0202},{"period":"1month","weight":-0.1733},{"period":"3month","weight":-0.1046},{"period":"6month","weight":-0.1019},{"period":"1year","weight":0.0034},{"period":"ytd","weight":-0.0521}],"compareEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.0069},{"period":"3month","weight":-0.006},{"period":"6month","weight":0.0464},{"period":"1year","weight":0.2148},{"period":"ytd","weight":0.029}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"哈尔滨誉衡药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"94400人(较上一季度增加1.29%)","perCapita":"22247股","listingDate":"2010-06-23","address":"黑龙江省哈尔滨市呼兰区利民经济技术开发区北京路29号","registeredCapital":"222986万元","survey":" 哈尔滨誉衡药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是维生素类药物、心脑血管药物、骨科药物、电解质类药物、抗肿瘤药物、抗感染药物、其他用药领域、糖尿病类药物、镇痛类药物。","listedPrice":50},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"誉衡药业(002437)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供誉衡药业(002437)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"誉衡药业,002437,誉衡药业股票,誉衡药业股票老虎,誉衡药业股票老虎国际,誉衡药业行情,誉衡药业股票行情,誉衡药业股价,誉衡药业股市,誉衡药业股票价格,誉衡药业股票交易,誉衡药业股票购买,誉衡药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"誉衡药业(002437)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供誉衡药业(002437)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}